BMS-646256 in Obese and Overweight Type 2 Diabetics
Status:
Withdrawn
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, randomized, double-blind, parallel arm, multicenter,
dose-ranging phase IIb trial to assess glycemic and weight loss efficacy and safety of
BMS-646256 in overweight and obese patients with type 2 diabetes who have been treated with
diet and exercise only or with half-maximal or greater metformin (≥1500mg/day) or
sulfonylurea monotherapy (stable dose for at least three months), but who remained
inadequately controlled (HbA1c >7% and HbA1c<10%).